About Generate Biomedicines Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://generatebiomedicines.com
Frequently Asked Questions
What is the 52-week range for GENB?
The 52-week high is $22.6699 and the 52-week low is $11.
What is the P/E ratio for GENB?
The P/E ratio data is currently unavailable.
What is the dividend yield for GENB?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
ROE data is currently unavailable.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
P/B ratio data is currently unavailable.
Analyst Recommendation Trends
Wall Street analyst consensus for GENB over the last few months:
Latest GENB News
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer
Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical trial underway at Roswell Park Treatment is designed to avoid pre-infusion chemotherapy and its side effects GB-5267 targets MUC16, a biomarker over-expressed in +80% of ovarian tumors BUFFALO, N.Y. and SOMERVILLE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Roswell Park Comprehensive Cancer Center (“Roswe
Roswell Park And Generate Biomedicines Announce First Patient Dosed In First-In-Human Clinical Trial Evaluating GB-5267, Investigational, Autologous IL-18 Armored CAR T-Cell Therapy
Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trialsFirst patient treated in new clinical trial underway at
Generate Biomedicines, Inc. (GENB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Generate Biomedicines, Inc. (GENB) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 7:00 AM EDTCompany ParticipantsMichael Nally -...
Absci's Billion-Dollar Hair Bet: Why The AI Story Doesn't Add Up
Absci is rated SELL, as its valuation is highly concentrated on ABS-201 with limited partner revenue and an early-stage pipeline. Click for more on ABSI.
AI Could Eventually Crack Cancer and Drug Discovery, Says Arm CEO — But This Is What’s Holding It Back
Arm Holdings PLC CEO Rene Haas said artificial intelligence could help find a cure for cancer within our lifetime, but warned that chip shortages are limiting the expansion of AI infrastructure. Haas said AI could eventually solve complex problems in...
HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Generate Biomedicines (NASDAQ:GENB) with a Buy and maintains $30 price target.
Generate Biomedicines Inc. to Participate in September Investor Conferences
SOMERVILLE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (Nasdaq: GENB) (“Generate”) today announced that members of its management team will participate in presentations at the following investor conferences: Cantor Global Healthcare Conference, New York, NY: Wednesday, Sept. 9 at 3:55 p.m. ET Morgan Stanley 24th Annual Global Healthcare Conference, New York, NY: Monday, Sept. 14 at 7:00 a.m. ET Goldman Sachs Life Sciences Symposium, New York, NY: Tuesday, Sept. 15 at 9:
How Nvidia’s Investment Juggernaut Can Jump from Big to Enormous
Nvidia has big investments in Intel, SpaceX and many more public companies. But its stakes in OpenAI and Anthropic are the real prize.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-01 | ARNOLD FRANCES | -1,000 | $16.002 | $16,002 |